EFPIA announces position against EMA draft policy

Pharmalive.com’s Ed Silverman reports that in another attempt to stop the European Medicines Agency (EMA) from continuing with their new policy for trial data disclosure, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has openly challenged the EMA’s policy saying it “would weaken safeguards for protecting patient privacy, undermine trust in the regulatory system, increase the risk data would be misinterpreted and weaken incentives for research.” The EFPIA has tried to meet the EMA somewhere in the middle over the topic of trial data disclosure, but each side has reverted back to its original stance. The EFPIA argues that the EMA is inconsistent with the current definition of CCI, an ordinance adopted by the EMA. And the EMA declares that scandals in the recent past associated with painkillers and anti-depressants have come from lack of data disclosure. Which side do you think is truly looking out for the consumer? For the full article click here.